Frits van Rhee

4 weeks ago | nature.com | Eric Siegel |Carolina Schinke |Frits van Rhee |Toshali Pandey

B-cell maturation antigen (BCMA) chimeric antigen receptor T (CAR T)-cell therapy has significantly advanced the treatment of relapsed/refractory (R/R) multiple myeloma (MM) [1]. In the phase II KarMMa trial, idecabtagene vicleucel (ide-cel) achieved a median progression-free survival (PFS) of 8.8 months and overall survival (OS) of 19.4 months in triple-class-exposed RRMM patients [2].

Aug 4, 2024 | nature.com | Molly Went |Gísli H. Halldórsson |Andrea Gunnell |Philip J Law |Amit Sud |Gudmar Thorleifsson | +24 more

AbstractMultiple myeloma (MM) is an incurable malignancy of plasma cells. Epidemiological studies indicate a substantial heritable component, but the underlying mechanisms remain unclear. Here, in a genome-wide association study totaling 10,906 cases and 366,221 controls, we identify 35 MM risk loci, 12 of which are novel.

Jul 12, 2024 | cancernetwork.com | Cesar G. Rodriguez |César Rodríguez |Frits van Rhee

July 12, 2024By Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape. Video content above is prompted by the following questions:What are your key takeaways on findings from the PERSEUS trial? What are some remaining unanswered questions from this trial? What will be important to evaluate in future analyses and research?

Jul 8, 2024 | patientpower.info | Frits van Rhee

Jul 5, 2024 | cancernetwork.com | Cesar G. Rodriguez |César Rodríguez |Frits van Rhee

July 5, 2024By Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.Video content above is prompted by the following questions:What are your initial impressions of the efficacy data from PERSEUS? What are the potential clinical implications of this data in your practice for TE NDMM patients? How might this data impact the current treatment landscape?